Amyris Biotechnologies Inc., an Emeryville, Calif.-based synthetic biology company focused on the development of pharmaceuticals, fine chemicals and biofuels, has raised $20 million in Series A funding. Khosla Ventures led the deal, and was joined by Kleiner Perkins Caufield & Byers and TPG Ventures. In related news, Amyris appointed John Melo as CEO. He previously was president of
Conduit Capital Partners of
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.